| Literature DB >> 22723897 |
Yan Liu1, Bing-quan Wu, Hao-hao Zhong, Xin-xia Tian, Wei-gang Fang.
Abstract
Telomerase plays important roles in the development and progression of malignant tumors, and its activity is primarily determined by transcriptional regulation of human telomerase reverse transcriptase (hTERT). Several mRNA alternative splicing variants (ASVs) for hTERT have been identified, but it remains unclear whether telomerase activity is directly associated with hTERT splicing transcripts. In this study, we developed novel real-time PCR protocols using molecular beacons and applied to lung carcinoma cell lines and cancerous tissues for quantification of telomerase activity and three essential hTERT deletion transcripts respectively. The results showed that lung carcinoma cell lines consistently demonstrated telomerase activity (14.22-31.43 TPG units per 100 cells) and various hTERT alternative splicing transcripts. For 165 lung cancer cases, telomerase activity showed significant correlation with tumor differentiation (poorly->moderately->well-differentiated, P<0.01) and with histotypes (combined small cell and squamous cell carcinoma>squamous cell carcinoma>adenosquamous carcinoma>adenocarcinoma, P<0.05). Although the overall hTERT transcripts were detected in all the samples, they were not associated with telomerase activity (r = 0.092, P = 0.24). Telomerase activity was significantly correlated with the transcriptional constituent ratio of α-deletion (r = -0.267, P = 0.026), β-deletion (r = -0.693, P = 0.0001) and γ-deletion (r = -0.614, P = 0.001). The positive rate and average constituent ratio of β-deletion transcripts (92.12%, 0.23) were higher than those of α-deletion (41.82%, 0.12) or γ-deletion (16.36%, 0.18) transcripts. The combined small-cell and squamous cell carcinomas expressed less deletion transcripts, especially β-deletion, than other histotypes, which might explain their higher telomerase activity. In conclusion, the molecular beacon-based real-time PCR protocols are rapid, sensitive and specific methods to quantify telomerase activity and hTERT ASVs. Telomerase activity may serve as a reliable and effective molecular marker to assist the evaluation of histological subtype and differentiation of lung carcinomas. Further studies on hTERT deletion splicing transcripts, rather than the overall hTERT transcripts, may improve our understanding of telomerase regulation.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22723897 PMCID: PMC3377688 DOI: 10.1371/journal.pone.0038868
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Linearity of the telomeric repeat amplification protocol (TRAP) using reverse primer-linked probe in cancer cell line.
Cell extracts equivalent to the indicated numbers of A549 cells were tested for telomerase activity. Results in gel electrophoresis (left), amplification plot (above) and standard curves (below) consistently indicated the linear relationship between the telomerase activity and A549 cell number, while 5 represented a negative control.
Quantification of telomerase activity and hTERT alternative splicing variants in tumor cell lines.
| Cell lines | Source | Telomerase activity | hTERT overall transcripts | hTERT alternative splicing variants | ||||||
| Relative expression | Constituent ratio | |||||||||
| α-deletiontranscripts | β-deletiontranscripts | γ-deletiontranscripts | α-deletiontranscripts | β-deletiontranscripts | γ-deletiontranscripts | |||||
| A549 | Lung adenocarcinoma | 31.43±6.47 | 17.00±2.92 | 4.25±2.14 | 2.44±0.68 | Not found | 0.25 | 0.14 | Not found | |
| SPC-A1 | Lung adenocarcinoma | 14.22±9.27 | 15.14±2.70 | 3.22±0.81 | 3.97±0.81 | 0.61±0.04 | 0.21 | 0.26 | 0.04 | |
| H1299 | Lung large cell carcinoma | 20.37±2.76 | 5.61±0.88 | 2.44±1.62 | 0.46±0.02 | Not found | 0.44 | 0.08 | Not found | |
| PAa | Lung adenocarcinoma | 21.42±3.57 | 14.80±3.73 | 4.25±1.17 | 1.98±1.61 | Not found | 0.29 | 0.13 | Not found | |
hTERT: human telomerase reverse transcriptase.
The means±standard deviation of duplicate determinations.
The means±standard deviation of triplicate determinations.
It was calculated by dividing the relative expression value of the overall transcripts by that of each deletion.
Figure 2Quantification of hTERT deletion splicing transcripts in SPC-A1 cell line using molecular beacons.
Representative linear amplification curves were shown for quantitative detection of overall hTERT (A), α-deletion (B), β-deletion (C) and γ-deletion (D) transcripts respectively. GAPDH served as an internal control. NC: negative control.
Figure 3Linearity of the telomeric repeat amplification protocol (TRAP) using reverse primer-linked probe in tumor tissue.
Serial diluted protein extracts from 2 µg to 0.0002 µg were tested for telomerase activity in one case of squamous cell carcinoma. Results in gel electrophoresis (left), amplification plot (above) and standard curves (below) consistently indicated the linear relationship between the telomerase activity and protein concentration, while 6 represented a negative control.
Quantification of telomerase activity and hTERT alternative splicing variants in lung tumor tissues.
| Telomerase activity | hTERT overall transcripts | hTERT alternative splicing variants | |||||||
| Variable | n | α-deletion transcripts | β-deletion transcripts | γ-deletion transcripts | |||||
| n | Constituentratio | n | Constituentratio | n | Constituentratio | ||||
| Sex | |||||||||
| Male | 115 | 30.72±19.44 | 41.92±22.91 | 50 | 0.11±0.04 | 107 | 0.20±0.11 | 19 | 0.09±0.04 |
| Female | 50 | 12.26±9.27 | 25.24±10.12 | 19 | 0.13±0.07 | 45 | 0.31±0.14 | 8 | 0.39±0.11 |
| Histological subtype | |||||||||
| Adc | 43 | 7.32±4.37 | 29.24±13.24 | 12 | 0.17±0.09 | 39 | 0.28±0.16 | 6 | 0.41±0.13 |
| Scc | 73 | 29.11±12.95 | 51.77±17.31 | 33 | 0.11±0.05 | 66 | 0.19±0.10 | 14 | 0.10±0.04 |
| ASc | 27 | 21.82±12.21 | 19.45±9.39 | 11 | 0.09±0.02 | 26 | 0.24±0.09 | 2 | 0.24±0.10 |
| CSS | 12 | 79.80±33.11 | 36.14±15.47 | 10 | 0.08±0.02 | 12 | 0.08±0.02 | 4 | 0.06±0.04 |
| Other | 10 | 15.94±7.86 | 8.74±3.75 | 3 | 0.24±0.12 | 9 | 0.50±0.30 | 1 | 0.33±0.16 |
| Differentiation | |||||||||
| Well | 30 | 8.09±4.77 | 36.70±14.46 | 6 | 0.17±0.06 | 25 | 0.22±0.15 | 4 | 0.20±0.13 |
| Moderately | 105 | 24.14±10.03 | 41.34±19.36 | 43 | 0.11±0.08 | 98 | 0.24±0.11 | 16 | 0.20±0.08 |
| Poorly | 30 | 46.35±16.72 | 20.68±7.98 | 20 | 0.12±0.05 | 30 | 0.22±0.11 | 7 | 0.18±0.09 |
| Stage | |||||||||
| I/II | 98 | 26.56±11.48 | 20.93±7.33 | 46 | 0.13±0.10 | 92 | 0.24±0.15 | 16 | 0.19±0.09 |
| III/IV | 67 | 23.03±11.09 | 60.17±27.49 | 23 | 0.09±0.06 | 61 | 0.22±0.16 | 11 | 0.16±0.07 |
| Pleural metastasis | |||||||||
| Yes | 83 | 18.42±9.72 | 31.37±16.39 | 31 | 0.14±0.05 | 77 | 0.27±0.18 | 10 | 0.20±0.12 |
| No | 82 | 31.91±13.69 | 42.42±18.35 | 38 | 0.10±0.04 | 75 | 0.19±0.10 | 17 | 0.17±0.05 |
| Lymph node metastasis | |||||||||
| Yes | 91 | 21.56±9.77 | 46.45±18.47 | 35 | 0.10±0.04 | 82 | 0.26±0.11 | 13 | 0.18±0.11 |
| No | 74 | 29.52±14.72 | 25.07±10.48 | 34 | 0.13±0.09 | 70 | 0.20±0.13 | 14 | 0.17±0.12 |
hTERT: human telomerase reverse transcriptase; Adc, adenocarcinoma; Scc, squamous cell carcinoma; ASc, adenosquamous carcinoma; CSS, combined small cell and squamous cell carcinoma.
The means±standard deviation of duplicate determinations.
The means±standard deviation of triplicate determinations.
It was calculated by dividing the relative expression value of the overall transcripts by that of each deletion.